Introduction {#sec1-1}
============

Cancer registration is an information system designed for the collection, management, storage, and analysis of data from people diagnosed with cancer. Cancer patients' demographic information and essential information about characteristics and treatment of tumors are collected (Zachary et al., 2015). In Korea, the national cancer database was constructed after the initiation of the national cancer registration project in 1980, and the annual national cancer registration report has been published every year since 2005. The Cancer Incidence in 5 Continents, Volume 9, published by the International Agency for Research on Cancer in 2007, included national cancer statistics and those from 8 regional cancer registries in Korea, improving the quality of cancer registration data from Korea (Annual Report of Cancer Statistics in Korea in 2012, 2014). As such, data management must begin even at the stage of data collection in order to ensure quality.

Accurate, complete, and timely cancer data can contribute to cancer management as evidence for cancer research, evaluation, and surveillance (Das, 2009; Steliarova et al., 2015). Representative indicators to evaluate the quality of cancer registration include comparability, completeness, validity, and timeliness, and various efforts should be made for accurate cancer registration during data collection to improve the indicators (Bray and Parkin, 2009; Larsen et al., 2009). To date, cancer registration staffs in hospitals have consulted the Korea Central Cancer Registry (KCCR) for desired information over the phone or using the inquiry corner of the homepage during cancer registration. Inquiries during cancer registration are largely related to cancer registration system or cancer registration staff. Inquiries about the cancer registration system indicate that issues remain unresolved by the guidelines or related training provided by the KCCR. Specifically, cancer registration items might be added, or cancer registration staff might be uninformed of changes and additions to tumor classification codes, which are critical for cancer registration. Moreover, utilizing an inquiry system, if present in a data collection system, can help improve the collected data's accuracy (Ortega et al., 2014). This function may not be used in cases of poor accessibility, delayed responses, or weak interaction (Boo et al., 2013). For cancer registration staffs, factors including the absence of devoted cancer registration staff, poor expertise, and insufficient training can cause cancer registration inquiries and lower the quality of cancer registration data (Boo et al., 2014).

Therefore, this study analyzed cancer registration inquiries to the KCCR and its responses, to investigate the inquiry functions in cancer registration and factors affecting the quality of cancer registration data.

Materials and Methods {#sec1-2}
=====================

Inquiry data on cancer registration obtained through the inquiry corner of the KCCR homepage from 2000 to 2014 were used. During that period, 721 questions were asked. Questions were divided into 9 types: subject of cancer registration (reportability); primary site (topography); histological diagnosis (histology); behavior; the Surveillance, Epidemiology, and the End Results Program (SEER) summary stage; most valid basis of diagnosis; first course of treatment; multiple primary tumors; and others. Questions with a low frequency or those about administrative procedures were categorized as "others." For response data that could be assigned ICD-O-3 (Fritz, 2000) and SEER summary stage codes (Adamo and Ruhl, 2015), codes used for responses were applied. Inquiry years were divided as 2000--2004, 2005--2009, and 2010--2014. In 2014, 170 hospitals were national cancer registration hospitals, comprising 32 hospitals with 100--300 beds, 66 with 301--600 beds, 59 with 601--1,000 beds, and 13 with 1001 or more beds (Subramanian et al., 2016).

Analysis {#sec2-1}
--------

Inquiry data from all 721 cases were compared depending on inquiry year, question type, and characteristics of the hospitals where inquirers were working. Descriptive analysis was performed to identify general characteristics of inquiries based on frequencies and percentages. A chi-square analysis was conducted to investigate significant differences in distribution characteristics by factors affecting quality of cancer registration data. The significance level was set to 10% for both sides. Stata version 14.1 (Stata Corp., College Station, Texas, USA) was used for all statistical analyses. MS Excel charting was used to investigate differences in inquiry contents depending on number of beds in hospitals.

Results {#sec1-3}
=======

Inquiry general characteristics {#sec2-2}
-------------------------------

The highest number of inquiry cases was between 2008 and 2010. Approximately 65% of the inquirers worked in hospitals in metropolitan cities. The largest number of cases was in the 601--1000 beds category with 439 cases (60.89%), followed by 177 cases with 1001 or more beds (24.55%), and 92 cases with 301--600 beds (12.76%). The hospital type with the highest numbers were tertiary hospitals with 468 cases (64.91%) and the question type with the highest numbers were histology with 353 cases (48.96%) ([Table 1](#T1){ref-type="table"}).

###### 

Inquiry General Characteristics

  Variable                           Subcategory        Frequency   Percentage
  --------------------------------- ------------------- ----------- ------------
                                    Total               721         100.0
  Inquiry year                      2000                10          1.39
  2001                              23                  3.19        
  2002                              5                   0.69        
  2003                              8                   1.11        
  2004                              20                  2.77        
  2005                              28                  3.88        
  2006                              28                  3.88        
  2007                              55                  7.63        
  2008                              142                 19.69       
  2009                              117                 16.23       
  2010                              122                 16.92       
  2011                              25                  3.47        
  2012                              25                  3.47        
  2013                              81                  11.23       
  2014                              32                  4.44        
  Question type                     Histology           353         48.96
  Primary site                      92                  12.76       
  Reportability                     76                  10.54       
  Summary stage                     64                  8.88        
  Behavior                          47                  6.52        
  Multiple primaries                32                  4.44        
  First course of treatment         29                  4.02        
  Most valid basis of diagnosis     25                  3.47        
  Others                            3                   0.42        
  Location                          Seoul               257         35.64
  Metropolitan cities               214                 29.68       
  Other regions                     250                 34.67       
  Hospital type                     Tertiary hospital   468         64.91
  General hospital                  245                 33.98       
  Hospital                          8                   1.11        
  Number of beds                    1,001 or more       177         24.55
  601--1,000                        439                 60.89       
  301--600                          92                  12.76       
  100--300                          13                  1.8         
  Regional cancer center hospital   No                  612         84.88
  Yes                               109                 15.12       

Detailed characteristics by period {#sec2-3}
----------------------------------

The highest number of questions in a period was 370 cases in 2005--2009, followed by 285 cases in 2010--2014 and 66 cases in 2000--2004 ([Table 2](#T2){ref-type="table"}). For question type by period, histology accounted for about half of all questions in all three periods, and there was no significant difference in distribution by year (P =.29). However, rates of questions for histology and multiple primaries gradually increased compared to other question types.

###### 

Question Type by Period

  Question type                   2000--2004            2005--2009           2010--2014            Total   
  ------------------------------- ------------ -------- ------------ ------- ------------ -------- ------- --------
  Histology                       29           43.94    172          46.49   152          53.33    353     48.96
  Primary site                    9            13.64    57           15.41   26           9.12     92      12.76
  Reportability                   4            6.06     43           11.62   29           10.18    76      10.54
  Summary stage                   6            9.09     36           9.73    22           7.72     64      8.88
  Behavior                        6            9.09     22           5.95    19           6.67     47      6.52
  Multiple primaries              2            3.03     16           4.32    14           4.91     32      4.44
  First course of treatment       6            9.09     10           2.70    13           4.56     29      4.02
  Most valid basis of diagnosis   4            6.06     12           3.24    9            3.16     25      3.47
  Others                          0            0.00     2            0.54    1            0.35     3       0.42
  Total                           66           100.00   370          100     285          100.00   721     100.00
  *P = 0.29*                                                                                               

Questions for histology were found in 353 cases (48.96%), corresponding to the highest number ([Table 3](#T3){ref-type="table"}). When 343 cases were analyzed (10 cases with no answers in the corresponding ICD-O-3 code were excluded), the histological diagnosis groups with the highest numbers of questions were as follows: adenoma and adenocarcinoma (814--838) with 122 cases (35.57%); ductal and lobular neoplasms (850--854) with 30 cases (8.75%); cystic, mucinous, and serous neoplasms (844--849) with 28 cases (8.16%); Hodgkin's and non-Hodgkin's lymphomas (959--972) with 20 cases (5.83%); and epithelial neoplasms (801--804) with 18 cases (5.25%). Cross-analysis of histological code groups by inquiry year with the three period groups showed a significant difference in distribution of questions by histological codes by period group (P \< .01).

###### 

Histology Question Analysis

  Category   Description                                             Frequency   \%      2000   2005   2010
  ---------- ------------------------------------------------------- ----------- ------- ------ ------ ------
  800        Neoplasms, NOS                                          8           2.33    \-     5      3
  801--804   Epithelial neoplasms, NOS                               18          5.25    3      6      9
  805--808   Squamous cell neoplasms                                 14          4.08    3      6      5
  809--811   Basal cell neoplasms                                    2           0.58    \-     1      1
  812--813   Transitional cell papillomas and carcinomas             8           2.33    \-     7      1
  814--838   Adenomas and adenocarcinomas                            122         35.57   7      51     64
  839--842   Adnexal and skin appendage neoplasms                    3           0.87    \-     2      1
  844--849   Mucoepidermoid neoplasms                                28          8.16    5      16     7
  850--854   Ductal and lobular neoplasms                            30          8.75    1      15     14
  855        Acinar cell neoplasms                                   5           1.46    \-     4      1
  856--857   Complex epithelial neoplasms                            10          2.92    2      8      \-
  858        Thymic epithelial neoplasms                             4           1.17    \-     \-     4
  859--867   Specialized gonadal neoplasms                           1           0.29    \-     1      \-
  880        Soft tissue tumors and sarcomas, NOS                    3           0.87    \-     2      1
  881--883   Fibromatous neoplasms                                   6           1.75    \-     4      2
  885--888   Lipomatous neoplasms                                    2           0.58    \-     1      1
  893--899   Complex mixed and stromal neoplasms                     6           1.75    1      2      3
  900--903   Fibroepithelial neoplasms                               1           0.29    \-     1      \-
  904        Synovial-like neoplasms                                 1           0.29    \-     \-     1
  906--909   Germ cell neoplasms                                     6           1.75    \-     2      4
  910        Trophoblastic neoplasms                                 2           0.58    2      \-     \-
  912--916   Blood vessel tumors                                     1           0.29    \-     \-     1
  918--924   Osseous and chondromatous neoplasms                     3           0.87    \-     3      \-
  935--937   Miscellaneous tumors                                    1           0.29    \-     \-     1
  938--948   Gliomas                                                 7           2.04    \-     1      6
  949--952   Neuroepitheliomatous neoplasms                          3           0.87    1      \-     2
  953        Meningiomas                                             2           0.58    \-     2      \-
  954--957   Nerve sheath tumors                                     3           0.87    \-     2      1
  959--972   Hodgkin's and non-Hodgkin's lymphomas                   20          5.83    1      12     7
  973        Plasma cell tumors                                      1           0.29    \-     \-     1
  975        Neoplasms of histiocytes and accessory lymphoid cells   3           0.87    1      \-     2
  976        Immunoproliferative diseases                            1           0.29    \-     1      \-
  980--994   Leukemia                                                8           2.33    \-     6      2
  995--996   Chronic myeloproliferative disorders                    5           1.46    \-     4      1
  997        Other hematologic disorders                             1           0.29    \-     \-     1
  998--999   Myelodysplastic syndromes                               4           1.17    1      1      2
  Total                                                              343         100     28     166    149
  P \< .01                                                                                             

When 90 cases of response data were analyzed, excluding 2 inquiry cases without the primary site code, the highest ranking primary sites were as follows: digestive organs with 20 cases (22.22%); lymph nodes with 14 cases (15.56%); hematopoietic and reticuloendothelial systems with 8 cases (8.89%); and eye, brain, and other parts of the central nervous system with 8 cases (8.89%) ([Table 4](#T4){ref-type="table"}). Cross-analysis of primary site by the three periods found no significant difference in the distribution (P = .11). The highest number of questions in 2000--2004 and 2005--2009 were for digestive organs, whereas respiratory system and intrathoracic organs had the highest number in 2010--2014. Hematopoietic and reticuloendothelial systems consistently showed a high number of questions during all periods. Most questions were about the stomach, large intestine, liver, and pancreas (digestive organs); lung and intrathoracic organs (respiratory system); and bone marrow, the primary site of leukemia in the hematopoietic and reticuloendothelial systems. The most frequent questions were for the top 10 common cancers.

###### 

Analysis of Question by Primary Site

  Category     Description                                             Frequency   Percentage   2000--2004   2005--2009   2010--2014
  ------------ ------------------------------------------------------- ----------- ------------ ------------ ------------ ------------
  C00-C14      Lip, oral cavity, and pharynx                           2           2.22         \-           1            1
  C15-C26      Digestive organs                                        20          22.22        3            15           2
  C30-C39      Respiratory system and intrathoracic organs             5           5.56         \-           1            4
  C40-C41      Bones, joints, and articular cartilage                  3           3.33         2            \-           1
  C42          Hematopoietic and reticuloendothelial systems           8           8.89         1            5            2
  C44          Skin                                                    2           2.22         \-           2            \-
  C48          Retroperitoneum and peritoneum                          2           2.22         \-           1            1
  C49          Connective, subcutaneous, and other soft tissues        6           6.67         1            2            3
  C50          Breast                                                  5           5.56         \-           3            2
  C51-C58      Female genital organs                                   4           4.44         1            2            1
  C60-C63      Male genital organs                                     3           3.33         1            1            1
  C64-C68      Urinary tract                                           1           1.11         \-           \-           1
  C69-C72      Eye, brain, and other parts of central nervous system   8           8.89         \-           7            1
  C73-C75      Thyroid and other endocrine glands                      4           4.44         \-           3            1
  C77          Lymph nodes                                             14          15.56        \-           11           3
  C80          Unknown primary site                                    3           3.33         \-           1            2
  Total                                                                90          100.00       9            55           26
  *P = 0.11*                                                                                                              

A total of 127 cases were in 19 combinations of specific primary sites and histology comprised ([Table 5](#T5){ref-type="table"}). For the combination of C16 (stomach) and 82113 (tubular adenocarcinoma), questions involved asking for histological codes to be given differently depending on differentiation, such as well or moderately differentiated adenocarcinoma, while questions for the combination of C16 (stomach) and 84903 (signet ring cell carcinoma) were for cases with inconsistent histological results from different tests, or about codes for histological sites with complex morphologies. Most questions for the combination of C18 (colon) and 81403 (adenocarcinoma), and of C18 (colon) and 82102 (adenocarcinoma in situ in adenomatous polyp), were for cases about different histological results from multiple tests, or about codes for tissues with complex behavior such as adenocarcinoma in tubular adenoma. The combination of C18 (colon) and 82403 (carcinoid tumor) was not yet included in ICD-O-3, though it was often used by clinicians, such as for neuroendocrine tumors. However, this was mostly found after 2009 along with behavior questions.

###### 

Common Histological Code Questions for Specific Primary Sites

  Topography   Morphology                                     Description                                           2000--2004   2005--2009   2010--2014   Total
  ------------ ---------------------------------------------- ----------------------------------------------------- ------------ ------------ ------------ -------
  C16          82113                                          Tubular adenocarcinoma                                0            6            0            6
               84903                                          Signet ring cell carcinoma                            0            3            2            5
  C18          81403                                          Adenocarcinoma                                        0            4            5            9
               82102                                          Adenocarcinoma in situ in adenomatous polyp           0            6            3            9
               82403                                          Carcinoid tumor                                       0            1            4            5
  C20          82401                                          Carcinoid tumor of uncertain malignant potential      1            3            2            6
  C22          81603                                          Cholangiocarcinoma                                    2            1            3            6
               81703                                          Hepatocellular carcinoma                              1            0            5            6
  C42.1        99643                                          Hypereosinophilic syndrome                            0            4            1            5
               99893                                          Myelodysplastic syndrome                              2            3            1            6
  C50          85003                                          Infiltrating ductal carcinoma                         1            7            3            11
               85073                                          Invasive micropapillary carcinoma                     0            3            3            6
  C67          81302                                          Papillary transitional cell carcinoma, non-invasive   0            3            2            5
  C72          95600                                          Neurilemmoma, schwannoma                              0            5            2            7
  C73          82603                                          Papillary carcinoma of thyroid                        1            6            1            8
  83403        Papillary adenocarcinoma, follicular variant   0                                                     3            3            6            
  83413        Papillary microcarcinoma                       1                                                     0            5            6            
  C77          95903                                          Malignant lymphoma                                    0            6            2            8
               96803                                          Malignant lymphoma, large B-cell, diffuse             0            4            3            7
                                                              Total                                                 9            68           50           127

Questions for C22 (liver) were for histological codes when different histological results were obtained from sites and when adenocarcinoma or cholangiocarcinoma were identified in the biliary track. Questions for C50 (breast) were for codes in cases in which behaviors were different in one tissue, histological results were different between bilateral breasts, histological results in a time series were different, or site-specific factors were mentioned in histological results.

Questions for C72 (spinal code, cranial nerve, and other parts of central nervous system) and 95600 (neurilemmoma) were for morphology codes to identify reportability after brain tumor registration. Most questions for C73 (thyroid) and 82603 (thyroid papillary carcinoma) were for cases to assign 82603 (thyroid papillary carcinoma) or 80503 (papillary carcinoma) codes for papillary carcinoma in the thyroid.

The first and second most common questions were for histology and primary site respectively, in both general and tertiary hospitals. There were more questions for reportability in general hospitals and for summary stage in tertiary hospitals. On the other hand, there were significant differences in question type by number of beds (P = .06). Summary stage questions accounted for 46.15% of questions from hospitals with 100--300 beds. Additionally, the most common question from hospitals with at least 300 beds was for histology, followed by primary site, reportability, and stage. There were significant differences in question type depending on hospital designation as a regional cancer center (P = .09). Questions for histology were asked more frequently from hospitals both with and without designation as a regional cancer center. Hospitals that were not regional cancer centers had about five times more questions (4.58%: 0.92%) for first course of treatment and about two times more questions for reportability (11.6%: 4.59%) than those designated as regional cancer centers ([Table 6](#T6){ref-type="table"}). Hospitals with 601--1000 beds asked the highest number of questions. As of 2014, 94 (55.3%) out of 170 hospitals subjected to cancer registration had asked questions. Hospitals with 601--1000 and 1001 or more beds had much more questions relative to the total number of cancer registration hospitals; smaller hospitals had fewer questions ([Table 7](#T7){ref-type="table"}).

###### 

Analysis of Inquiries by the Affiliated Hospital of the Inquirers Institution

  Question type          Hospital type                                         Number of beds                         Designation as regional cancer center                               
  ---------------------- --------------- ------- ----- ---------- ---- ------- ---------------- ------- ----- ------- --------------------------------------- ------- ----- ------- ----- -------
  Behavior               17              7       30    6.42       0    0       8                8.7     20    4.64    19                                      10.73   41    6.7     6     5.5
  First course of        13              5.35    16    3.43       0    0       6                6.52    18    4.18    5                                       2.82    28    4.58    1     0.92
  treatment                                                                                                                                                                               
  Histology              109             44.86   240   51.39      4    30.77   49               53.26   204   47.33   92                                      51.98   286   46.73   67    61.47
  Others                 2               0.82    1     0.21       0    0       0                0       20    4.64    4                                       2.26    23    3.76    2     1.83
  Method for diagnosis   13              5.35    11    2.36       1    7.69    3                3.26    19    4.41    9                                       5.08    26    4.25    6     5.5
  Multiple primaries     7               2.88    25    5.35       0    0       1                1.09    1     1       1                                       0.56    78    12.75   14    12.84
  Primary Site           34              13.99   57    12.21      1    7.69    12               14.13   61    14.15   16                                      9.04    71    11.6    5     4.59
  Reportability          22              9.05    53    11.35      1    7.69    7                7.61    47    10.9    20                                      11.3    56    9.15    8     7.34
  Summary stage          28              11.52   35    7.49       6    46.15   5                5.43    41    9.51    11                                      6.21    3     0.49    0     0
  Total                  245             100     468   100        13   100     92               100     431   100     177                                     100     612   100     109   100
                         P = 0.06                      P = 0.06                                                       P = 0.09                                                            

###### 

Analysis of Utilization of Inquiry System by Number of Beds

  Number of beds                                                           100--300    301--600    601--1,000   1,001 or more   Total
  ------------------------------------------------------------------------ ----------- ----------- ------------ --------------- -----------
  Cancer registration hospital (%)                                         32 (18.8)   66 (38.8)   59 (34.7)    13 (7.6)        170 (100)
  Number of questions (%)                                                  13 (1.8)    92 (12.8)   439 (60.9)   177 (24.5)      721 (100)
  Number of hospitals questioned (except duplicated questioned hospital)   6           30          45           13              94
  Inquiry performance rate (%)                                             (6.4)       (31.9)      (47.9)       (13.8)          \(100\)

For questions on histology, the highest number of questions was for 814--838 (adenomas and adenocarcinomas) in all sizes of hospitals. Questions with the highest numbers from hospitals with 601--1,000 and 1001 or more beds were for 959--972 (Hodgkin's and non-Hodgkin's lymphomas), 850--854 (ductal and lobular neoplasms), and 844--849 (cystic, mucinous, and serous neoplasms). Inquiries with the highest numbers for primary site were for C15--C26 (digestive organs) and C51--C58 (female genital organs) in all sizes of hospitals. In addition, hospitals with 1000 or more beds asked questions mostly for C73--C75 (thyroid and other endocrine glands) and C42 (hematopoietic and reticuloendothelial systems). Hospitals with 601--1,000 beds had questions mostly for C50 (breast), C30--C39 (respiratory and intrathoracic organs), C77 (lymph nodes), and C69--C72 (eye, brain, and other parts of central nervous system) ([Figure 1](#F1){ref-type="fig"}).

![Analysis of Inquiry by Number of Beds](APJCP-18-1663-g001){#F1}

Discussion {#sec1-4}
==========

Sometimes cancer registration staffs are not confident about the codes to be given during cancer registration. They may encounter medical records of cancer patients in which their clinical knowledge or information on the cancer registration guidelines are insufficient for completing the task of coding. In this regard, the cancer registration inquiry system will be a highly effective consultation method, contributing to improved quality of collected cancer registration data.

The National Program of Cancer Registries in the Unites States recommends operation of a cancer inquiry response system as one of the major activities to be focused on at cancer registration sites (Subramanian et al., 2016). This study found that the number of inquiries on cancer registration gradually increased every year in Korea. In particular, the number of inquiries increased whenever cancer registration items were added or changed. For example, in 2005, this included the addition of brain tumor. Then, in 2012, these included diagnosis path, laterality, differentiation, metastasized site and the guidelines were revised. In 2013, the Collaborative Stage project was executed. Therefore, the inquiry system of the National Cancer Registration Center functioned as a communication channel with cancer registration hospitals as intended. However, this inquiry system is currently operated by a closed system where questions can be asked only by signing up as a member and logging in to the website of the training center for cancer registration. Moreover, answers are given only to the inquirer, making it difficult to share inquiry results. The system should be improved to share inquiry information and develop an open system like the inquiry system of the SEER Program in the United States (Bernal, 2011).

There were a number of inquiries on histology from hospitals of all sizes regardless of hospital type, except from those with 100--300 beds. There were many inquiries for specific histological codes in certain primary sites. This finding is consistent with the results of a report that indicated if insufficient information about histology classification was provided for liver and intrahepatic duct carcinoma, papillary carcinoma of thyroid, and colonic neuroendocrine tumor, or the terms used by clinicians and pathologists were inconsistent, this could lead to choosing incorrect codes for cancer registration (Brewster, 2002; Altekruse et al., 2011; Kay, 2013). If the same questions are asked repeatedly, it will be necessary to add and announce new guidelines reflecting the opinions of an expert committee and to institute a training program.

Most primary site inquiries were for digestive organs (C15--C26); lymph nodes (C77); hematopoietic and reticuloendothelial systems (C42), and eye, brain, and other parts of the central nervous system (C69--C72). There were more inquiries for eye, brain, and other parts of the central nervous system (C69-C72) in 2005--2009, which may be due to expansion of the scope to benign brain tumor for cancer registration. Questions for lymph nodes (C77) and hematopoietic and reticuloendothelial systems (C42) were continuously asked, which may be due to changes in the codes on the classification system and terms. Specifically, it was found that continuous training and related information must be provided for cancer registration staff to deliver accurate information on items updated or added to the cancer registration system.

In the interaction between cancer registration hospitals and the National Cancer Registration Center for accurate cancer registration information, large cancer registration hospitals had more inquiries when compared with small hospitals. Therefore, the National Cancer Registration Center should make efforts to interact with hospital staff through evaluation of participation in training by cancer registration staff and quality of cancer registration data. In the analysis of question type by hospital, there were a number of questions to be reported for cancer registration from general hospitals, which reflects the characteristics that a significant number of cancer patients only had initial diagnosis in general hospitals without specific examination and moved to tertiary hospitals; therefore, there might be a lack of clinical information to make a decision for cancer registration, or general hospital staff might have insufficient knowledge for cancer registration. Questions for the summary stage accounted for 46.15% of questions from hospitals with 100--300 beds, whereas larger hospitals commonly had more questions on histological codes. Furthermore, tertiary hospitals had more questions for diagnosis methods, which might reflect that they were applying various advanced surgeries, treatments, and examinations more than general hospitals.

There were differences depending on designation as a regional cancer center. A significantly higher number of questions for first course of treatment and reportability in non-designated hospitals seem to be due to a lack of cancer registration experience. Therefore, focusing on frequent inquiry items from general hospital staff and providing training that includes missing information related to cancer registration would be beneficial. In order to increase the accuracy of cancer registration and improve performance, describing cases of the most common or frequent questions in the cancer registration guidelines to provide staff with opportunities for indirect experiences is necessary. It is also necessary to improve training by focusing on questions that pertain to increasing trends. Regardless of hospital type, number of beds, and designation as a regional cancer center hospital, items with the highest number of inquiries by cancer registration staff were histology and primary site. In the long term, it is necessary to provide students with opportunities to experience various cases of cancer registration during cancer registration-related training courses in colleges. Furthermore, it is an effective way to improve quality by training cancer registration staff for cases with frequent questions before working with cancer registration.

In this study, it was difficult to identify characteristics of individual inquirers because information about experiences and knowledge of each individual inquirer could not be ascertained. Therefore, it was not possible to determine the relationship between cancer registration inquiries and the experiences or skill level of individual inquirers.

Consistency and accuracy of response to inquiry greatly affect the quality and reliability of cancer registration data, increasing the ability to activate an interaction between the National Cancer Registration Center and cancer registration staff in hospitals. If clear information cannot be provided in response to an inquiry, or if response time lengthens, this might affect data quality. Therefore, an expert committee should be established that can rapidly respond to inquiries, and it is necessary to prepare related procedures. This would link cancer registration staff of medical institutions extracting cancer registration data with cancer registration centers that collect and manage the data, and enable active sharing of information that will be able to bring about expansion and advancement of the National Cancer Registration Project.
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